within Pharmacolibrary.Drugs.ATC.H;

model H05BX03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.716666666666667e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0048,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0349,
    k12             = 1.68,
    k21             = 1.68
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H05BX03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Doxercalciferol is a synthetic vitamin D2 analog used in the management of secondary hyperparathyroidism in patients with chronic kidney disease, especially those on dialysis. It is an approved drug with active use in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult hemodialysis patients after a single intravenous dose.</p><h4>References</h4><ol><li><p>Dennis, VC, &amp; Albertson, GL (2006). Doxercalciferol treatment of secondary hyperparathyroidism. <i>The Annals of pharmacotherapy</i> 40(11) 1955–1965. DOI:<a href=&quot;https://doi.org/10.1345/aph.1G523&quot;>10.1345/aph.1G523</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17062838/&quot;>https://pubmed.ncbi.nlm.nih.gov/17062838</a></p></li><li><p>Upton, RA, et al., &amp; LeVan, LW (2003). Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 18(4) 750–758. DOI:<a href=&quot;https://doi.org/10.1093/ndt/gfg030&quot;>10.1093/ndt/gfg030</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12637645/&quot;>https://pubmed.ncbi.nlm.nih.gov/12637645</a></p></li><li><p>Bailie, GR, &amp; Johnson, CA (2002). Comparative review of the pharmacokinetics of vitamin D analogues. <i>Seminars in dialysis</i> 15(5) 352–357. DOI:<a href=&quot;https://doi.org/10.1046/j.1525-139x.2002.00086.x&quot;>10.1046/j.1525-139x.2002.00086.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12358640/&quot;>https://pubmed.ncbi.nlm.nih.gov/12358640</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H05BX03;
